FindTrial
Sign In

PD-1 blocking antibody

DRUG8 trials

Sponsors

Sun Yat-sen University, Ruijin Hospital, Peking University Third Hospital

Conditions

Nasopharyngeal CarcinomaPD-1 InhibitorsPancreatic CancerRecurrent Nasopharyngeal CarcinomaSolid TumorStereotactic Body Radiotherapy

Phase 2

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
Active, not recruitingNCT03930498
Sun Yat-sen UniversityRecurrent Nasopharyngeal Carcinoma
Start: 2020-03-12End: 2025-12-31Target: 68Updated: 2025-01-28
Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
CompletedNCT03984357
Sun Yat-sen UniversityNasopharyngeal Carcinoma
Start: 2020-03-16End: 2025-03-30Updated: 2025-07-17
Umbrella Biomarker-Guided Therapy in NPC
Not yet recruitingNCT04605562
Sun Yat-sen UniversityNasopharyngeal Carcinoma
Start: 2022-06-30End: 2026-12-31Target: 206Updated: 2021-09-05
Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients
NCT05097781
Ruijin HospitalSolid Tumor
Start: 2021-03-21End: 2024-09-30Target: 55Updated: 2021-10-28

Phase 3

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
RecruitingNCT03907826
Sun Yat-sen UniversityRecurrent Nasopharyngeal Carcinoma
Start: 2020-03-01End: 2028-12-31Target: 212Updated: 2025-01-28
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
Active, not recruitingNCT04907370
Sun Yat-sen UniversityNasopharyngeal Carcinoma
Start: 2021-08-01End: 2027-03-01Updated: 2025-07-16
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
RecruitingNCT06239727
Sun Yat-sen UniversityNasopharyngeal Carcinoma
Start: 2024-03-01End: 2030-02-20Target: 593Updated: 2026-03-06

Unknown Phase

Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer
CompletedNCT06195254
Peking University Third HospitalPancreatic Cancer, PD-1 Inhibitors, Stereotactic Body Radiotherapy
Start: 2020-12-01End: 2023-12-15Updated: 2024-01-08

Related Papers

Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma
JAMA2025-08-2111 citations
PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial.
Journal of Clinical Oncology2025-06-042 citations
Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial.
Journal of Clinical Oncology2025-05-28
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial.
2025-02-2714 citations
Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.
Journal of Clinical Oncology2024-08-10
Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial.
Journal of Clinical Oncology2024-06-013 citations
TIRA study: A phase III, multicenter, randomized controlled study of toripalimab plus radical chemoradiotherapy with or without concurrent cisplatin in patients with high-risk locoregionally advanced nasopharyngeal carcinoma.
Journal of Clinical Oncology2022-06-013 citations